Zev Aryeh Wainberg MD

Oncology•Santa Monica, CA

Professor, Medicine, UCLA School of Medicine

Join to View Full Profile

2020 Santa Monica Blvd., Suite 600Santa Monica, CA 90404
Phone+1 310-570-1472
Fax+1 310-570-1472

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2000 - 2003
Tel Aviv University SacklerClass of 2000

Certifications & Licensure

CA State Medical License 2003 - 2027
NY State Medical License 2001 - 2003
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Start of enrollment: 2007 Dec 01
Completed
Phase 2
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer Start of enrollment: 2009 Sep 01
Completed
Phase 2
Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
Completed
Phase 1
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Start of enrollment: 2011 Jan 03
Completed
Phase 1
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors Start of enrollment: 2012 Nov 27
Terminated
Phase 1, Phase 2
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Start of enrollment: 2012 Nov 23
Completed
Phase 2
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 1
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors Start of enrollment: 2013 Aug 01
Terminated
Phase 1
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors Start of enrollment: 2013 Nov 19
Completed
Phase 1, Phase 2
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2014 Jun 12
Completed
Phase 1
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Start of enrollment: 2016 Feb 19
Completed
Phase 1
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer Start of enrollment: 2019 Jul 24
COMPLETED
EARLY_PHASE1
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors Start of enrollment: 2020 Feb 20
TERMINATED
EARLY_PHASE1
Join now to see all

Publications & Presentations

PubMed

FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma.
Elizabeth C Smyth, Kyoung-Mee Kim, Sun Young Rha, Zev A Wainberg, Hayden Honeycutt
Cancer Treatment Reviews. 2025-09-01
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results.
Zev A Wainberg, Colin D Weekes, Muhammad Furqan, Pashtoon M Kasi, Craig E Devoe
Nature Medicine. 2025-08-11
1 citations
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.
Kohei Shitara, Sylvie Lorenzen, Jin Li, Yuxian Bai, Manuel González Fernández
Journal of Clinical Oncology. 2025-08-01

Journal Articles

Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-Line, Advanced Gastric Cancer
Al Benson, Zev A Wainberg, JAMA Oncology

Lectures

First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC).
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase ...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) can...
2019 ASCO Annual Meeting - 6/1/2019
Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin ...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Join now to see all

Press Mentions

The Six Signs of Pancreatic Cancer You Should Never IgnoreAugust 23rd, 2025
Cancer Vaccine Shows Early Promise in Hard-to-Treat TumorsAugust 21st, 2025
Cancer Vaccine Shows Promising Results in UCLA Clinical TrialAugust 17th, 2025
Join now to see all

Grant Support

Causes and Consequences of Adenosine Signaling in Pancreatic CancerUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2029
Causes and Consequences of Adenosine Signaling in Pancreatic CancerUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2029
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancerUNIVERSITY OF CALIFORNIA LOS ANGELES2021–2026

Zev Aryeh Wainberg MD

Dr. Wainberg is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.